Novo Nordisk received clinical approval for oral PCSK9 inhibitor NNC0385-0434 tablets

Text|Pharmaceutical Mission Hills

According to the latest announcement by the Center for Drug Evaluation (CDE) of the State Drug Administration of China, Novo Nordisk has declared a Class 1 new drug NNC0385-0434 tablets, which has obtained the implied license for clinical trials.

Screenshot source: CDE official website

High levels of LDL-C in the blood are also called "bad" cholesterol, which can increase the risk of serious cardiovascular events in patients

Subtilisin converting enzyme 9 (PCSK9) is a liver protease

Based on this principle, a number of PCSK9 inhibitors have been successfully developed clinically for atherosclerotic cardiovascular disease (ASCVD), familial hypercholesterolemia, and reducing heart attack and stroke in patients with cardiovascular disease And diseases such as the risk of angina pectoris that require hospitalization

It is worth mentioning that most of the PCSK9 inhibitors currently on the market are monoclonal antibody drugs in the form of injections

Public information shows that Novo Nordisk is currently conducting a phase 2 clinical trial to study how NNC0385-0434 tablets can reduce cholesterol in people at high risk of heart disease or heart disease

Reference materials:

[1] Center for Drug Evaluation of China National Medical Products Administration.